Navigation Links
Cardiac Science Appoints Dave Marver as Chief Operating Officer
Date:11/3/2008

BOTHELL, Wash., Nov. 3 /PRNewswire-FirstCall/ -- Cardiac Science (Nasdaq: CSCX) a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced the appointment today of David L. Marver as Executive Vice President and Chief Operating Officer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

"We created the COO position to build our strategic capabilities at a senior level," said John Hinson, Cardiac Science President and CEO. "Dave impressed us with his strategic insight and global perspective as well as his broad operations and sales management experience. We are delighted to welcome him to Cardiac Science."

In this new role, Mr. Marver will report to Mr. Hinson and will manage the daily operations of the company.

Mr. Marver brings to Cardiac Science significant medical device experience from his 14 years at Medtronic, where he held a number of senior leadership positions with large businesses including Cardiac Rhythm Management, Cardiac Surgery, and Diabetes. His roles at Medtronic included Vice President Strategy & Business Development, Vice President Sales, Vice President Marketing, and Vice President Product Strategy.

Mr. Marver also spent three years at Medtronic's International Headquarters, where he led commercial activities for Medtronic's Cardiac Rhythm Management business in Western Europe. In addition, he has significant experience in device informatics and connectivity, having served as US Business Director for Medtronic's Patient Management business.

In addition to his Medtronic experience, Mr. Marver served as an Operations Manager for Accellent, a component supplier to the device industry. He also worked in human resources consulting with the HayGroup and as a Partner with Omega Fund Management, a life sciences investor.

Mr. Marver earned his BA from Duke University and his MBA from the Anderson School at the University of California, Los Angeles.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

For more information,

Company Contact: Investor Contact: Media Contact:

Mike Matysik Doug Sherk Christopher Gale

Cardiac Science Corporation Jenifer Kirtland EVC Group, Inc.

Sr. Vice President and CFO EVC Group, Inc. (646) 201-5431

(425) 402-2009 (415) 896-6820 (203) 570-4681

cgale@evcgroup.com


'/>"/>
SOURCE Cardiac Science
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
2. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
3. Cardiac Science Announces Inclusion in Russell 3000 Index
4. CardiacAssist, Inc. Surpasses 1300 TandemHeart System Procedures
5. Cardiac Science Launches Anywhere Data Management for HIS and EMR Systems
6. Braemar Introduces the ER920W Wireless Cardiac Arrhythmia Monitor
7. Cardiac Science to Present at Needham Biotechnology & Medical Technology Conference
8. Perceptive Informatics Enhances Medical Imaging Capabilities for Assessment of Cardiac Function
9. Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates
10. CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair
11. CryoLife Conducts Surgeons Cardiac Allograft Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; ... Friday, February 24, 2017 a total of 10,672,750 common share ... per common share. Proceeds from the exercise of these warrants ... Treasury.   ... "We are grateful for this expression of confidence by our ...
(Date:2/27/2017)... and HAMILTON, Bermuda ... (NASDAQ: ADXS ) and ... companies focused on developing cancer immunotherapies, today announced ... develop a novel cancer immunotherapy agent using Advaxis, ... SELLAS, patented WT1 targeted heteroclitic peptide antigen mixture ...
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... can be safely completed in an ambulatory surgery center (ASC) with satisfactory clinical ... and previous two-year TDR studies. , Jake Lubinski, president of AxioMed, commented ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
Breaking Biology News(10 mins):